SCYNEXIS (135A) Price & Analysis

Compare

1 Followers

135A Stock Chart & Stats

€0.64

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.64

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.48 - €0.98

Previous CloseN/A

Volume0.00

Average Volume (3M)433.00

Market Cap

€34.94M

Enterprise Value€22.03M

Total Cash (Recent Filing)€40.11M

Total Debt (Recent Filing)€2.17M

Price to Earnings (P/E)―

Beta0.06

Next Earnings

May 18, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.22

Shares Outstanding44,663,834

10 Day Avg. Volume1,175

30 Day Avg. Volume433

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)0.64

Price to Sales (P/S)1.53

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.61

Price Target Upside307.89% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.05

Revenue Forecast (FY)€22.14M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetMaterial reduction in debt and a sizable equity base provide durable financial flexibility. This strengthens the company’s ability to fund commercialization, clinical programs, or partnerships without immediate reliance on dilutive financing, improving resilience over a multi‑quarter horizon.

Approved Commercial Product (Brexafemme)Having an FDA‑approved, orally administered antifungal creates a lasting commercial foundation. Approval enables recurring product sales, payer relationships, and partnering/licensing optionality that support sustained revenue potential beyond short-term market swings.

Demonstrated Revenue Recovery And Prior Cash InflectionThe company has shown it can generate large inflectional cash and revenue under certain conditions. This indicates latent commercial or licensing levers that, if replicated or scaled, could sustainably convert R&D investment into positive cash generation over the medium term.

Bears Say

Negative Margins / Ongoing LossesSustained negative margins reflect that current commercial scale and pricing do not cover fixed costs. Persistent losses can erode equity, force cost cutting, or require external capital, limiting the company’s ability to invest consistently in commercialization or new indications.

Negative And Volatile Free Cash FlowContinued negative FCF leaves the company exposed to financing risk for operations and trials. Cyclical cash generation makes planning and multi‑period investments harder, increasing likelihood of financing, partnership concessions, or delayed programs if inflows don’t stabilize.

Highly Volatile Top‑line HistoryLarge year‑to‑year swings imply revenue depends on episodic events (one‑time deals, milestone receipts, or irregular sales) rather than steady market adoption. That undermines forecasting, commercial scaling, and payer/partner confidence across multi‑quarter planning horizons.

SCYNEXIS News

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

SCYNEXIS (SCYX) announced that the first participants have been dosed in a Phase 1 single ascending dose and...

20d ago

SCYX

Cero Therapeutics appoints Eric Francois to board of directors

CERo Therapeutics Holdings (CERO) announces the appointment of Eric Francois to the Company’s Board of Directors. Formerly, he...

29d ago

CERO

SCYX

Scynexis announces presentation highlighting data from SCY-247

Scynexis (SCYX) announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural...

2M ago

SCYX

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

Scynexis (SCYX) announced that the U.S. Food and Drug Administration, FDA, has granted the Company Qualified Infectious Disease...

2M ago

SCYX

Scynexis granted 180-day extension by Nasdaq to regain compliance

SCYNEXIS (SCYX) announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market to regain...

3M ago

SCYX

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

SCYNEXIS Inc ($SCYX) announced an update on their ongoing clinical study. Study Overview: SCYNEXIS Inc. (SCYX) is running...

3M ago

SCYX

Scynexis completes transfer of BREXAFEMME NDA to GSK

SCYNEXIS (SCYX) announced that it has completed the transfer of the BREXAFEMME New Drug Application, NDA, to GSK...

4M ago

GSK

SCYX

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

SCYNEXIS (SCYX) announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among...

4M ago

SCYX

SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating

SCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim...

4M ago

SCYX

SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

SCYNEXIS Inc ( ($SCYX) ) has released its Q3 earnings. Here is a breakdown of the information SCYNEXIS...

4M ago

SCYX

Scynexis reports Q3 EPS (17c), consensus (20c)

Reports Q3 revenue $334,000, consensus $147,670. “Over the last several weeks, SCYNEXIS (SCYX) realized two significant achievements that...

4M ago

SCYX

SCYX Upcoming Earnings Report: What to Expect?

SCYNEXIS Inc (SCYX) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street analysts...

4M ago

SCYX

Scynexis price target lowered to $3 from $4 at Guggenheim

Guggenheim lowered the firm’s price target on Scynexis (SCYX) to $3 from $4 and keeps a Buy rating...

5M ago

GSK

SCYX

SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

5M ago

SCYX

135A FAQ

What was SCYNEXIS Inc’s price range in the past 12 months?

SCYNEXIS Inc lowest stock price was €0.48 and its highest was €0.98 in the past 12 months.

What is SCYNEXIS Inc’s market cap?

SCYNEXIS Inc’s market cap is €34.94M.

When is SCYNEXIS Inc’s upcoming earnings report date?

SCYNEXIS Inc’s upcoming earnings report date is May 18, 2026 which is in 61 days.

How were SCYNEXIS Inc’s earnings last quarter?

SCYNEXIS Inc released its earnings results on Mar 04, 2026. The company reported €0.218 earnings per share for the quarter, beating the consensus estimate of €0.111 by €0.107.

Is SCYNEXIS Inc overvalued?

According to Wall Street analysts SCYNEXIS Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SCYNEXIS Inc pay dividends?

SCYNEXIS Inc does not currently pay dividends.

What is SCYNEXIS Inc’s EPS estimate?

SCYNEXIS Inc’s EPS estimate is -0.1.

How many shares outstanding does SCYNEXIS Inc have?

SCYNEXIS Inc has 44,663,834 shares outstanding.

What happened to SCYNEXIS Inc’s price movement after its last earnings report?

SCYNEXIS Inc reported an EPS of €0.218 in its last earnings report, beating expectations of €0.111. Following the earnings report the stock price went up 0.773%.

Which hedge fund is a major shareholder of SCYNEXIS Inc?

Currently, no hedge funds are holding shares in DE:135A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SCYNEXIS Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€2.61 (307.89% Upside)

Technicals

Fundamentals

Return on Equity

-19.05%

Trailing 12-Months

Asset Growth

-34.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS (135A) Earnings & Revenues

Historic Earnings Reports

135A Stock 12 Month Forecast

Average Price Target

€2.61

▲(307.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.61047985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.61047985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.61047985,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.627,0.779575373076923,0.9321507461538461,1.0847261192307691,1.2373014923076924,1.3898768653846152,1.5424522384615384,1.6950276115384615,1.8476029846153845,2.000178357692308,2.1527537307692306,2.3053291038461534,2.457904476923077,{"y":2.61047985,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.627,0.779575373076923,0.9321507461538461,1.0847261192307691,1.2373014923076924,1.3898768653846152,1.5424522384615384,1.6950276115384615,1.8476029846153845,2.000178357692308,2.1527537307692306,2.3053291038461534,2.457904476923077,{"y":2.61047985,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.627,0.779575373076923,0.9321507461538461,1.0847261192307691,1.2373014923076924,1.3898768653846152,1.5424522384615384,1.6950276115384615,1.8476029846153845,2.000178357692308,2.1527537307692306,2.3053291038461534,2.457904476923077,{"y":2.61047985,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.934,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.857,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.848,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.746,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.559,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.588,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.691,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.669,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.566,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.574,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.516,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.629,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.627,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >